Sangamo Therapeutics - SGMO Stock Forecast, Price & News

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Wall Street Analyst Weigh In

SGMO has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 11th. Wedbush reiterated a "neutral" rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Monday, June 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.75.

Sangamo Therapeutics Stock Performance

SGMO Stock opened at $6.33 on Monday. The firm's 50-day moving average price is $4.41 and its two-hundred day moving average price is $4.89. Sangamo Therapeutics has a 12-month low of $3.12 and a 12-month high of $11.49.

Sangamo Therapeutics (NASDAQ:SGMO - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. Sangamo Therapeutics had a negative net margin of 150.96% and a negative return on equity of 48.06%. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $24.63 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts anticipate that Sangamo Therapeutics will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Sangamo Therapeutics

In related news, Director John Markels purchased 6,784 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, June 3rd. The shares were bought at an average price of $3.69 per share, for a total transaction of $25,032.96. Following the completion of the transaction, the director now directly owns 32,484 shares of the company's stock, valued at $119,865.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.60% of the company's stock.